Handelsbanken Fonder Ab Astrazeneca PLC Transaction History

Handelsbanken Fonder Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$61.03 - $69.57 $995,155 - $1.13 Million	-16,306 Reduced 80.6%	3,924 $266,000
Q2 2022 Aug 03, 2022	SELL	$59.26 - $71.14 $71,112 - $85,368	-1,200 Reduced 5.6%	20,230 $1.34 Million
Q1 2022 May 11, 2022	SELL	$55.72 - $67.12 $1.24 Million - $1.5 Million	-22,300 Reduced 50.99%	21,430 $1.42 Million
Q4 2021 Feb 08, 2022	SELL	$54.02 - $63.83 $518,592 - $612,768	-9,600 Reduced 18.0%	43,730 $2.55 Million
Q3 2021 Nov 10, 2021	BUY	$55.56 - $60.79 $2.96 Million - $3.24 Million	53,330 New	53,330 $3.2 Million

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $203B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.